Please select the option that best describes you:

For what sort of SLE clinical profile do you favor anifrolumab beyond patients with prominent skin manifestations?  



Answer from: at Academic Institution
Sign In or Register to read more

Answer from: at Community Practice
Sign In or Register to read more